{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:59:48Z","timestamp":1781153988555,"version":"3.54.1"},"reference-count":165,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Triple combination therapy with the CFTR modulators elexacaftor (ELX), tezacaftor (TEZ) and ivacaftor (IVA) has been qualified as a game changer in cystic fibrosis (CF). We provide an overview of the body of literature on ELX\/TEZ\/IVA published between November 2019 and February 2023 after approval by the regulators. Recombinant ELX\/TEZ\/IVA-bound Phe508del CFTR exhibits a wild type conformation<jats:italic>in vitro<\/jats:italic>, but in patient\u2019s tissue a CFTR glyoisoform is synthesized that is distinct from the wild type and Phe508del isoforms. ELX\/TEZ\/IVA therapy improved the quality of life of people with CF in the real-life setting irrespective of their anthropometry and lung function at baseline. ELX\/TEZ\/IVA improved sinonasal and abdominal disease, lung function and morphology, airway microbiology and the basic defect of impaired epithelial chloride and bicarbonate transport. Pregnancy rates were increasing in women with CF. Side effects of mental status changes deserve particular attention in the future.<\/jats:p>","DOI":"10.3389\/fphar.2023.1158207","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:30:57Z","timestamp":1679373057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor\u2014Ivacaftor"],"prefix":"10.3389","volume":"14","author":[{"given":"Burkhard","family":"T\u00fcmmler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jcf.2022.01.008","article-title":"Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype","volume":"21","author":"Aalbers","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B2","doi-asserted-by":"publisher","first-page":"jcs259002","DOI":"10.1242\/jcs.259002","article-title":"Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs","volume":"135","author":"Abu-Arish","year":"2022","journal-title":"J. Cell Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"L119","DOI":"10.1152\/ajplung.00639.2020","article-title":"CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling","volume":"321","author":"Anderson","year":"2021","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"00023","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","author":"Arslan","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jcf.2022.06.004","article-title":"Eruptive melanocytic naevi following initiation of elexacaftor\/ivacaftor\/tezacaftor for cystic fibrosis","volume":"21","author":"Atkinson","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101776","DOI":"10.1016\/j.rmcr.2022.101776","article-title":"Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor","volume":"40","author":"Balmpouzis","year":"2022","journal-title":"Respir. Med. Case Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"110421","DOI":"10.1016\/j.ejrad.2022.110421","article-title":"Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report","volume":"154","author":"Bec","year":"2022","journal-title":"Eur. J. Radiol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","author":"Beck","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2100671","DOI":"10.1183\/13993003.00671-2021","article-title":"The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor","volume":"59","author":"Becq","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.7326\/M22-1741","article-title":"Challenged urine bicarbonate excretion as a measure of cystic fibrosis transmembrane conductance regulator function in cystic fibrosis","volume":"175","author":"Berg","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","article-title":"Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease","volume":"20","author":"Bermingham","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: Deep learning CT analysis and patient-reported outcomes","volume":"19","author":"Beswick","year":"","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jcf.2021.09.014","article-title":"Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy","volume":"21","author":"Beswick","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jcf.2022.06.011","article-title":"A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment","volume":"21","author":"Bhaskaran","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jcf.2021.12.006","article-title":"Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers","volume":"21","author":"Bijvelds","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis","author":"Bode","year":"2023","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"2023","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/ijms22105262","article-title":"Partial rescue of F508del-CFTR stability and trafficking defects by double corrector treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic Fibrosis Patients with F508del\/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor\/Tezacaftor\/Ivacaftor Treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J. Clin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/alr.23036","article-title":"Improvement in sinonasal quality-of-life indicators for pediatric patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"13","author":"Castellanos","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2200725","DOI":"10.1183\/13993003.00725-2022","article-title":"Elexacaftor-Tezacaftor-Ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis","volume":"2022","author":"Cavinato","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jcte.2022.100311","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e247042","DOI":"10.1136\/bcr-2021-247042","article-title":"Elexacaftor, tezacaftor and ivacaftor: A case of severe rash and approach to desensitisation","volume":"15","author":"Cheng","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/jpm12040632","article-title":"Theratyping of the rare CFTR variants E193K and R334W in rectal organoid-derived epithelial monolayers","volume":"12","author":"Ciciriello","year":"2022","journal-title":"J. Pers. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/antibiotics10070828","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with the F508del\/Unknown Genotype","volume":"10","author":"Comegna","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100307","DOI":"10.1016\/j.jcte.2022.100307","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e46450","DOI":"10.7554\/eLife.46450","article-title":"Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations","volume":"8","author":"Csan\u00e1dy","year":"2019","journal-title":"Elife"},{"key":"B34","doi-asserted-by":"publisher","first-page":"26334","DOI":"10.1002\/ppul.26334","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment reduces airway inflammation in cystic fibrosis","volume":"2023","author":"De Vuyst","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2202096","DOI":"10.1183\/13993003.02096-2022","article-title":"Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis","volume":"61","author":"Dhote","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5863\/1551-6776-27.5.463","article-title":"Rechallenge of elexacaftor\/tezacaftor\/ivacaftor after skin rash in two pediatric patients","volume":"27","author":"Diseroad","year":"2022","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/alr.22716","article-title":"Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis","volume":"11","author":"Douglas","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"00281","DOI":"10.1016\/j.pulmoe.2022.11.007","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor modulator on lung structure in cystic fibrosis","author":"Fainardi","year":"2023","journal-title":"Pulmonology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"00655","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","author":"Fajac","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","article-title":"Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction","volume":"20","author":"Farinha","year":"2013","journal-title":"Chem. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcf.2022.01.007","article-title":"Measuring the effect of elexacaftor\/tezacaftor\/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography","volume":"21","author":"FitzMaurice","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B46","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/children10020252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: A cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Child. (Basel)."},{"key":"B48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcf.2021.07.006","article-title":"Response to elexacaftor\/tezacaftor\/ivacaftor in intestinal organoids derived from people with cystic fibrosis","volume":"21","author":"Furstova","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1164\/rccm.202001-0180OC","article-title":"Recombinant acid ceramidase reduces inflammation and infection in cystic fibrosis","volume":"202","author":"Gardner","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/genes14020449","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on cardiorespiratory polygraphy parameters and respiratory muscle strength in cystic fibrosis patients with severe lung disease","volume":"14","author":"Giallongo","year":"2023","journal-title":"Genes (Basel)."},{"key":"B52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdcr.2021.10.018","article-title":"Urticaria multiforme-like eruption due to a novel agent elexacaftor\/tezacaftor\/ivacaftor in a pediatric patient with cystic fibrosis","volume":"18","author":"Goldberg","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.3390\/jcm11206160","article-title":"Dynamic perfluorinated gas MRI shows improved lung ventilation in people with cystic fibrosis after elexacaftor\/tezacaftor\/ivacaftor: An observational study","volume":"11","author":"Goralski","year":"2022","journal-title":"J. Clin. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"206","author":"Graeber","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: A case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1515\/cclm-2021-0724","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Habler","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/jpet.117.241497","article-title":"Altering metabolic profiles of drugs by precision deuteration 2: Discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development","volume":"362","author":"Harbeson","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1096\/fj.12-216119","article-title":"Correctors of \u0394F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein","volume":"27","author":"He","year":"2013","journal-title":"FASEB J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B61","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/(SICI)1098-1004(1997)9:4<332::AID-HUMU5>3.0.CO","article-title":"Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis","volume":"9","author":"Highsmith","year":"1997","journal-title":"Hum. Mutat."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0110422","DOI":"10.1128\/aac.01104-22","article-title":"Physiologically based pharmacokinetic modeling to guide management of drug interactions between elexacaftor-tezacaftor-ivacaftor and antibiotics for the treatment of nontuberculous mycobacteria","volume":"66","author":"Hong","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/postgradmedj-2020-139264","article-title":"Triple therapy' (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis","volume":"98","author":"Hu","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1164\/rccm.202101-0090LE","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improved clinical outcomes in a patient with N1303K-CFTR based on in vitro experimental evidence","volume":"204","author":"Huang","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/mol.117.108373","article-title":"Direct binding of the corrector VX-809 to human CFTR NBD1: Evidence of an allosteric coupling between the binding site and the NBD1:CL4 interface","volume":"92","author":"Hudson","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: The MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"","journal-title":"BMJ Open Respir. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e17427","DOI":"10.7759\/cureus.17427","article-title":"Cystic fibrosis transmembrane conductance regulator modulators during pregnancy: A case series","volume":"13","author":"Kendle","year":"2021","journal-title":"Cureus"},{"key":"B71","doi-asserted-by":"publisher","first-page":"166955","DOI":"10.1016\/j.jmb.2021.166955","article-title":"Co-translational folding of the first transmembrane domain of ABC-transporter CFTR is supported by assembly with the first cytosolic domain","volume":"433","author":"Kleizen","year":"2021","journal-title":"J. Mol. Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.3390\/cimb44100349","article-title":"Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]","volume":"44","author":"Kondratyeva","year":"","journal-title":"Curr. Issues Mol. Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"10377","DOI":"10.3390\/ijms231810377","article-title":"Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy","volume":"23","author":"Kondratyeva","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jcf.2014.04.003","article-title":"Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels","volume":"13","author":"Kopeikin","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"B75","doi-asserted-by":"publisher","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front. Pediatr."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e01015","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1074\/jbc.AC119.011360","article-title":"CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor","volume":"295","author":"Krainer","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1111\/bph.14475","article-title":"Potentiation of the cystic fibrosis transmembrane conductance regulator by VX-770 involves stabilization of the pre-hydrolytic O1 state","volume":"175","author":"Langron","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/jpm11040301","article-title":"Phenotyping rare CFTR mutations reveal functional expression defects restored by TRIKAFTATM","volume":"11","author":"Laselva","year":"2021","journal-title":"J. Pers. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/jpm12101577","article-title":"Elexacaftor\/tezacaftor\/ivacaftor accelerates wound repair in cystic fibrosis airway epithelium","volume":"12","author":"Laselva","year":"2022","journal-title":"J. Pers. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1124\/mol.118.111799","article-title":"Correctors of the major cystic fibrosis mutant interact through membrane-spanning domains","volume":"93","author":"Laselva","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"S1569","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"27","author":"Lee","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: Preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e138722","DOI":"10.1172\/jci.insight.138722","article-title":"Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta","volume":"5","author":"Liessi","year":"2020","journal-title":"JCI Insight"},{"key":"B85","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2017.03.020","article-title":"Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR","volume":"136","author":"Loo","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","author":"Lopez","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B88","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5863\/1551-6776-27.5.467","article-title":"If at first you don't succeed, trikafta again","volume":"27","author":"Loyd","year":"2022","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"11396","DOI":"10.3390\/ijms231911396","article-title":"Modulator combination improves in vitro the microrheological properties of the airway surface liquid of cystic fibrosis airway epithelia","volume":"23","author":"Ludovico","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFabd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.resmer.2021.100829","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir. Med. Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B93","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccm.2022.06.010","article-title":"Nontuberculous mycobacterial infections in cystic fibrosis","volume":"43","author":"Martiniano","year":"2022","journal-title":"Clin. Chest Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B95","doi-asserted-by":"publisher","first-page":"00434","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): Results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","author":"Mayer-Hamblett","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis","volume":"21","author":"McKinzie","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B97","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/cod.14002","article-title":"Toxic epidermal necrolysis induced by cystic fibrosis transmembrane conductance regulator modulators","volume":"86","author":"Mederos-Luis","year":"2022","journal-title":"Contact Dermat."},{"key":"B98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J. Drug Assess."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor-tezacaftor- ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Can. J. Ophthalmol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/prot.25496","article-title":"Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site","volume":"86","author":"Molinski","year":"2018","journal-title":"Proteins"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2100185","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/ppul.25938","article-title":"At-home compounding preparation of slow desensitization of elexacaftor\/tezacaftor\/ivacaftor for delayed hypersensitivity rash","volume":"57","author":"Muirhead","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"Promise: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B106","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.therap.2022.01.020","article-title":"Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy","volume":"77","author":"Nuytten","year":"2022","journal-title":"Therapie"},{"key":"B108","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: A two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B109","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamadermatol.2022.5208","article-title":"Acneiform eruption following elexacaftor-tezacaftor-ivacaftor treatment in patients with cystic fibrosis","volume":"159","author":"Okroglic","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B111","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1153656","article-title":"Differential effects of ELX\/TEZ\/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G","volume":"14","author":"Pallenberg","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jcf.2021.10.005","article-title":"CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the \u03b2-adrenergic sweat rate assay","volume":"21","author":"Pallenberg","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"","journal-title":"Microbiol. Spectr."},{"key":"B114","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B115","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J. Clin. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e17229","DOI":"10.7759\/cureus.17229","article-title":"Chronic joint pain in a young adult with cystic fibrosis","volume":"13","author":"Prajapati","year":"2021","journal-title":"Cureus"},{"key":"B117","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ppul.25779","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis post liver transplant: A case series","volume":"57","author":"Ragan","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B119","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1091\/mbc.E13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell."},{"key":"B120","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: A high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2201402","DOI":"10.1183\/13993003.01402-2022","article-title":"Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021","volume":"61","author":"Ringshausen","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B122","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jaci.2020.05.041","article-title":"Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes","volume":"147","author":"Roehmel","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.jcf.2020.04.017","article-title":"Testicular pain following initiation of elexacaftor\/tezacaftor\/ivacaftor in males with cystic fibrosis","volume":"19","author":"Rotolo","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B124","doi-asserted-by":"publisher","first-page":"123518","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B126","doi-asserted-by":"publisher","first-page":"101553","DOI":"10.1016\/j.rmcr.2021.101553","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","author":"Schnell","year":"2023","journal-title":"Liver Int."},{"key":"B128","doi-asserted-by":"publisher","first-page":"01384","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","author":"Schwarzenberg","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B129","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B130","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jcf.2022.06.003","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis","volume":"21","author":"Shakir","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B131","doi-asserted-by":"publisher","first-page":"L305","DOI":"10.1152\/ajplung.00388.2021","article-title":"Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway","volume":"322","author":"Shaughnessy","year":"","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci. Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jcf.2022.02.011","article-title":"Net benefit of ivacaftor during prolonged tezacaftor\/elexacaftor exposure in vitro","volume":"21","author":"Shaughnessy","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B134","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients: The Value of the ex vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B136","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1114584","DOI":"10.3389\/fphar.2023.1114584.2023.1114584","article-title":"Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy","volume":"14","author":"Stanke","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B140","doi-asserted-by":"publisher","first-page":"00006","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","author":"Steinack","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B141","doi-asserted-by":"publisher","first-page":"01432","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"2023","author":"Streibel","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B142","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B143","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B144","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/genes12081178","article-title":"Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del\/Unknown and Advanced Lung Disease","volume":"12","author":"Terlizzi","year":"2021","journal-title":"GenesGenes (Basel)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"00008","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","author":"Tewkesbury","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B147","doi-asserted-by":"publisher","first-page":"01425","DOI":"10.1016\/j.jcf.2022.12.005","article-title":"Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background","author":"Tomati","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B148","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm. Ther."},{"key":"B149","volume-title":"Mutation-specific therapies in cystic fibrosis","author":"T\u00fcmmler","year":"2022"},{"key":"B150","doi-asserted-by":"publisher","first-page":"00504","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: Randomised, double-blind, controlled, phase 2 trials","volume":"2023","author":"Uluer","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"B151","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jcf.2007.07.007","article-title":"CFTR protein analysis of splice site mutation 2789+5 G-A","volume":"7","author":"van Barneveld","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"B152","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sc.i U. S. A."},{"key":"B153","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B154","doi-asserted-by":"publisher","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"B156","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B157","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/jpm11070643","article-title":"A precision medicine approach to optimize modulator therapy for rare CFTR folding mutants","volume":"11","author":"Veit","year":"","journal-title":"J. Pers. Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7812\/TPP\/21.089","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor on hospitalizations and intravenous antibiotic use","volume":"26","author":"Walter","year":"2022","journal-title":"Perm. J."},{"key":"B160","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1159\/000524773","article-title":"Effect of triple combination CFTR modulator therapy on sleep in adult patients with cystic fibrosis","volume":"101","author":"Welsner","year":"2022","journal-title":"Respiration"},{"key":"B161","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jcf.2022.02.005","article-title":"CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis","volume":"21","author":"Westh\u00f6lter","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B162","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor\/Tezacaftor\/Ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B163","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","volume":"57","author":"Wright","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"2022","author":"Zhang","year":"","journal-title":"Eur. Respir. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1158207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T08:35:49Z","timestamp":1680165349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1158207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":165,"alternative-id":["10.3389\/fphar.2023.1158207"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1158207","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"article-number":"1158207"}}